{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T03:12:25Z","timestamp":1788232345360,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.phrs.2020.105040","type":"journal-article","created":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T23:51:20Z","timestamp":1592869880000},"page":"105040","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"special_numbering":"C","title":["Targeting T cells in inflammatory bowel disease"],"prefix":"10.1016","volume":"159","author":[{"given":"Paolo","family":"Giuffrida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Di Sabatino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2020.105040_bib0005","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/j.cgh.2020.01.028","article-title":"Changing global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century","volume":"18","author":"Ananthakrishnan","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.phrs.2020.105040_bib0010","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.autrev.2015.08.004","article-title":"New insights into immune mechanisms underlying autoimmune diseases of the gastrointestinal tract","volume":"14","author":"Di Sabatino","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.phrs.2020.105040_bib0015","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10620-017-4892-4","article-title":"Old and new lymphocyte players in inflammatory bowel disease","volume":"63","author":"Giuffrida","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.phrs.2020.105040_bib0020","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1136\/gut.25.1.32","article-title":"Intestinal lymphocyte subpopulations in inflammatory bowel disease: an analysis by immunohistological and cell isolation techniques","volume":"25","author":"Selby","year":"1984","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0025","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/BF01318690","article-title":"Immunohistological characterization of intraepithelial and lamina propria lymphocytes in control ileum and colon and in inflammatory bowel disease","volume":"31","author":"Hirata","year":"1986","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.phrs.2020.105040_bib0030","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/0016-5085(91)90729-5","article-title":"Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease","volume":"101","author":"Schreiber","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0035","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1136\/gut.31.12.1365","article-title":"Differential expression of CD25 (interleukin-2 receptor) on lamina propria T cells and macrophages in the intestinal lesions in Crohn\u2019s disease and ulcerative colitis","volume":"31","author":"Choy","year":"1990","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0040","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1053\/j.gastro.2007.03.025","article-title":"CD4+NKG2D+ T cells in Crohn\u2019s disease mediate inflammatory and cytotoxic responses through MICA interactions","volume":"132","author":"Allez","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0045","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1053\/j.gastro.2011.03.061","article-title":"Activation of the receptor NKG2D leads to production of Th17 cytokines in CD4+ T cells of patients with Crohn\u2019s disease","volume":"141","author":"Pariente","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0050","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0016-5085(97)70128-8","article-title":"Interleukin 12 is expressed and actively released by Crohn\u2019s disease intestinal lamina propria mononuclear cells","volume":"112","author":"Monteleone","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0055","doi-asserted-by":"crossref","first-page":"143","DOI":"10.4049\/jimmunol.163.1.143","article-title":"Bioactive IL-18 expression is up-regulated in Crohn\u2019s disease","volume":"163","author":"Monteleone","year":"1999","journal-title":"J Immunol"},{"key":"10.1016\/j.phrs.2020.105040_bib0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.gastro.2005.05.002","article-title":"Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution","volume":"129","author":"Heller","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0065","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/eji.201343524","article-title":"Absence of a role for interleukin-13 in inflammatory bowel disease","volume":"44","author":"Biancheri","year":"2014","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.phrs.2020.105040_bib0070","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/gut.2009.182170","article-title":"Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease","volume":"58","author":"Rovedatti","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0075","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1136\/gut.2007.135053","article-title":"IL23 differentially regulates the Th1\/Th17 balance in ulcerative colitis and Crohn\u2019s disease","volume":"57","author":"Kobayashi","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0080","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/ecco-jcc\/jjx039","article-title":"Gammadelta T cells in Crohn\u2019s disease: a new player in the disease pathogenesis?","volume":"11","author":"Catalan-Serra","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105040_bib0085","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.4049\/jimmunol.1202959","article-title":"Proinflammatory V\u03b42+ T cells populate the human intestinal mucosa and enhance IFN-\u03b3 production by colonic \u03b1\u03b2 T cells","volume":"191","author":"McCarthy","year":"2013","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2020.105040_bib0090","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1172\/JCI80840","article-title":"Azathioprine therapy selectively ablates human V\u03b42+ T cells in Crohn\u2019s disease","volume":"125","author":"McCarthy","year":"2015","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2020.105040_bib0095","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1093\/ecco-jcc\/jjw066","article-title":"Regional specialisation of T cell subsets and apoptosis in the human gut mucosa: differences between ileum and colon in healthy intestine and inflammatory bowel diseases","volume":"10","author":"Carrasco","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105040_bib0100","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1053\/j.gastro.2007.08.035","article-title":"A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis","volume":"133","author":"Plevy","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0105","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ibd.21084","article-title":"Prospective randomized open-label multicenter phase I\/II dose escalation trial of visilizumab (HuM291) in severe steroid-refractory ulcerative colitis","volume":"16","author":"Baumgart","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105040_bib0110","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1136\/gut.2009.205443","article-title":"Anti-CD3 antibody visilizumab is not effective in patients with intravenous corticosteroid-refractory ulcerative colitis","volume":"59","author":"Sandborn","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0115","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/ibd.21252","article-title":"Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn\u2019s disease","volume":"16","author":"van der Woude","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105040_bib0120","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1053\/j.gastro.2014.03.049","article-title":"A CD3-specific antibody reduces cytokine production and alters phosphoprotein profiles in intestinal tissues from patients with inflammatory bowel disease","volume":"147","author":"Vossenk\u00e4mper","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0125","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1046\/j.1365-2036.1996.59201000.x","article-title":"Treatment of severe Crohn\u2019s disease with anti-CD4 monoclonal antibody","volume":"10","author":"Canva-Delcambre","year":"1996","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105040_bib0130","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gut.40.3.320","article-title":"CD4 antibody treatment in patients with active Crohn\u2019s disease: a phase 1 dose finding study","volume":"40","author":"Stronkhorst","year":"1997","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1365-2036.2003.01639.x","article-title":"Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis","volume":"18","author":"Creed","year":"2003","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105040_bib0140","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1111\/j.1365-2036.2006.02904.x","article-title":"Basiliximab for the treatment of steroid-resistant ulcerative colitis: further experience in moderate and severe disease","volume":"23","author":"Creed","year":"2006","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2020.105040_bib0145","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1053\/j.gastro.2012.04.043","article-title":"Basiliximab does not increase efficacy of corticosteroids in patients with steroid-refractory ulcerative colitis","volume":"143","author":"Sands","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0150","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0002-9270(02)05907-5","article-title":"A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis","volume":"98","author":"Van Assche","year":"2003","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105040_bib0155","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/gut.2005.089854","article-title":"Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial","volume":"55","author":"Van Assche","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0160","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1136\/gutjnl-2016-311824","article-title":"Anti-NKG2D monoclonal antibody (NNC0142-0002) in active Crohn\u2019s disease: a randomised controlled trial","volume":"66","author":"Allez","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0165","doi-asserted-by":"crossref","first-page":"4049","DOI":"10.4049\/jimmunol.163.7.4049","article-title":"Hyperexpression of CD40 ligand (CD154) in inflammatory bowel disease and its contribution to pathogenic cytokine production","volume":"163","author":"Liu","year":"1999","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2020.105040_bib0170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.addr.2018.12.005","article-title":"Targeting the CD40-CD40L pathway in autoimmune diseases: humoral immunity and beyond","volume":"141","author":"Karnell","year":"2019","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.phrs.2020.105040_bib0175","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1136\/gut.2005.079392","article-title":"Fontolizumab, a humanised anti-interferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn\u2019s disease","volume":"55","author":"Hommes","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0180","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1136\/gut.2005.079434","article-title":"A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn\u2019s disease","volume":"55","author":"Reinisch","year":"2006","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0185","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/ibd.21038","article-title":"Fontolizumab in moderate to severe Crohn\u2019s disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study","volume":"16","author":"Reinisch","year":"2010","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105040_bib0190","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1136\/gutjnl-2014-308004","article-title":"Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study","volume":"64","author":"Danese","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0195","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1136\/gutjnl-2014-308337","article-title":"Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study","volume":"64","author":"Reinisch","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0200","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.autrev.2019.03.012","article-title":"The role of interleukin-13 in chronic inflammatory intestinal disorders","volume":"18","author":"Giuffrida","year":"2019","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.phrs.2020.105040_bib0205","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn\u2019s disease: unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0210","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1056\/NEJMoa1602773","article-title":"Ustekinumab as induction and maintenance therapy for Crohn\u2019s disease","volume":"375","author":"Feagan","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105040_bib0215","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2020.105040_bib0220","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1146\/annurev.immunol.19.1.497","article-title":"Calcium signaling mechanisms in T lymphocytes","volume":"19","author":"Lewis","year":"2001","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.phrs.2020.105040_bib0225","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nri1632","article-title":"NFAT proteins: key regulators of T-cell development and function","volume":"5","author":"Macian","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.phrs.2020.105040_bib0230","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.ceca.2019.03.004","article-title":"CRAC channels and disease - From human CRAC channelopathies and animal models to novel drugs","volume":"80","author":"Feske","year":"2019","journal-title":"Cell Calcium"},{"key":"10.1016\/j.phrs.2020.105040_bib0235","doi-asserted-by":"crossref","first-page":"3454","DOI":"10.4049\/jimmunol.0802887","article-title":"Targeting gut T cell Ca2+ release-activated Ca2+ channels inhibits T cell cytokine production and T-box transcription factor T-bet in inflammatory bowel disease","volume":"183","author":"Di Sabatino","year":"2009","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2020.105040_bib0240","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1093\/ecco-jcc\/jjw053","article-title":"Mechanism of action of anti-TNF therapy in inflammatory bowel disease","volume":"10","author":"Levin","year":"2016","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105040_bib0245","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1097\/01.MIB.0000194185.69800.07","article-title":"Caspase activation and apoptosis induction by adalimumab: demonstration in vitro and in vivo in a chimeric mouse model","volume":"12","author":"Shen","year":"2006","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105040_bib0250","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1097\/MIB.0b013e318280b169","article-title":"The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factor \u03b1","volume":"19","author":"Ueda","year":"2013","journal-title":"Inflamm. Bowel Dis."},{"key":"10.1016\/j.phrs.2020.105040_bib0255","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1136\/gut.53.1.70","article-title":"Defective mucosal T cell death is sustainably reverted by infliximab in a caspase dependent pathway in Crohn\u2019s disease","volume":"53","author":"Di Sabatino","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0260","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.crohns.2012.09.006","article-title":"The influence of infliximab and adalimumab on the expression of apoptosis-related proteins in lamina propria mononuclear cells and enterocytes in Crohn\u2019s disease - an immunohistochemical study","volume":"7","author":"Eder","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105040_bib0265","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1053\/j.gastro.2011.08.032","article-title":"Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14+ macrophages","volume":"141","author":"Atreya","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2020.105040_bib0270","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1136\/gut.2006.105379","article-title":"Prediction of antitumour necrosis factor clinical efficacy by real-time visualisation of apoptosis in patients with Crohn\u2019s disease","volume":"56","author":"Van den Brande","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.phrs.2020.105040_bib0275","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1038\/ctg.2017.44","article-title":"Transmembrane TNF-\u03b1 density, but not soluble TNF-\u03b1 level, is associated with primary response to infliximab in inflammatory bowel disease","volume":"8","author":"Amini Kadijani","year":"2017","journal-title":"Clin. Transl. Gastroenterol."},{"key":"10.1016\/j.phrs.2020.105040_bib0280","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1080\/17474124.2018.1494573","article-title":"How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease","volume":"12","author":"Naviglio","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"issue":"6","key":"10.1016\/j.phrs.2020.105040_bib0285","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD000545.pub3","article-title":"Azathioprine or 6-mercaptopurine for induction of remission in Crohn\u2019s disease","author":"Prefontaine","year":"2010","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.phrs.2020.105040_bib0290","article-title":"Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis","author":"Timmer","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2020.105040_bib0295","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.crohns.2012.06.020","article-title":"In vitro\" azathioprine-induced changes in peripheral T cell apoptosis and IFN-\u03b3 production associate with drug response in patients with Crohn\u2019s Disease","volume":"7","author":"Cossu","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"10.1016\/j.phrs.2020.105040_bib0300","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00005-014-0309-7","article-title":"Cyclosporine A regulates pro-inflammatory cytokine production in ulcerative colitis","volume":"63","author":"Steiner","year":"2015","journal-title":"Arch Immunol Ther Exp (Warsz)"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661820313487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:23:46Z","timestamp":1760912626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661820313487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":60,"alternative-id":["S1043661820313487"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105040","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting T cells in inflammatory bowel disease","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2020.105040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105040"}}